Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients.

An adjuvant chemotherapeutic standard has not been identified in triple negative breast cancer (TNBC) yet. One hundred and forty-one adjuvant treated TNBC patients had a median follow-up of 71 months. Larger tumor size (p = .